IDH1 and glioma: The known genetic determinants of immunotherapy response in gliomas, including somatic mutations in IDH, are limited, and the present findings identify a common germline SNP linked to potential immunologic differences that may help inform clinical decision-making and be leveraged for the development of more effective immunotherapies.